Rejuvenation is no longer just for the human face, it’s potentially for humanity, according to a small biotech that claims to have developed technology that extends the lifespan of mice by 7%.

Although the breakthrough hasn’t been peer-reviewed, it’s from San Diego Rejuvenate organic claims that it was successful in reprogramming the genes of small rodents, resulting in mice living an average of 18 weeks longer than controls after treatment, after to the MIT Technology Review.

What it means for humans: Vittorio Sebastianoprofessor on Stanford University, advised against testing the technology on humans. However, the scientific director of Rejuvenate Bio Noah Davidsohn sees a potential application for seniors.

See also: Could Bezos return as Amazon CEO in 2023?

“This is powerful technology and here is the proof of concept,” Davidsohn said, according to the report, adding that he “wanted to show that it’s actually something we can do in our older population.”

Rejuvenate Bio isn’t the only biotech company trying to find a cure for death. Amazon.com, Inc AMZN founder jeff bezos Invested $3 billion in a biotech startup Altos Labs a year ago, after to Popular Mechanics. Like Rejuvenate Bio, Altos works to harness cellular rejuvenation to reverse disease and ultimately aging.

The concern: Aside from the physical concerns of testing the technology in humans, which has been shown to cause cancer in mice, the cost to humans who could gain access to FDA-approved cellular rejuvenation would be high if it ever came to that.

This could mean that only the richest in the world could afford to extend their lives, which would give the rich another way to get richer, adding to their wealth during borrowed time. While there’s already a long-term gender divide between empires, bioethicists are picking up University of Utrecht, Christopher Warehamfears the gap between rich and poor could widen if science confirms methods that…